Sanofi
Frexalimab
Multiple Sclerosis
Countdown
303days
Phase 3 readout · May 6, 2027
What's at stake
Phase 3 trial results for Frexalimab in Multiple Sclerosis are due May 6, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 14h ago
“CT.gov NCT06141473: Phase 3 trial, sponsor Sanofi, drug Frexalimab. Primary completion date 2027-05-06 (estimated).”